Lobe Sciences Ltd. (LOBEF) es una empresa que cotiza en bolsa en el Salud sector, operando dentro de la Drug Manufacturers - Specialty & Generic industria. La empresa tiene su sede en Vancouver, BC, Canada. El CEO actual es Frederick Dominick Sancilio.
LOBEF tiene fecha de IPO 2023-08-24, cotiza en el Other OTC, una capitalización de mercado de $12.77M.
Lobe Sciences Ltd., a life sciences company, focuses on the research and development of psychedelic medicines. It develops psilocybin-based therapeutics in combination with N-acetylcysteine for the treatment of mild traumatic brain injuries and post-traumatic stress disorder, as well as devices for the efficient application of medications. The company was formerly known as Greenstar Biosciences Corp. and changed its name to Lobe Sciences Ltd. in November 2020. Lobe Sciences Ltd. is headquartered in Vancouver, Canada.
